The authors report preliminary results of a study performed on six patients with by advanced, hormone-refractory prostate cancer. These patients were treated by estramustine phosphate (10 mg/kg) and methotrexate (60 mg/mq). Low toxicity allows the use of this therapy in outpatient regimens. Moreover, the high rate of partial responses (five patients) shows the remarkable efficacy of this therapy, even if follow-up and number of patients are not sufficient to reach definitive conclusions.
EinserbergerM.A.: Chemotherapy for advanced prostate cancer. In “The medical management of prostate cancer” pg. 75–86, DenisL. ed., Springer-Verlag, 1991.
2.
KozlowskiJ.M.: Chemotherapy: editorial. J. Urol., 147: 938–941, 1992.
3.
LoeningS.A., BeckeleyS., BradyM.F.: Comparison of estramustine phospathe, methotrexate and cisplatinum in patients with advanced, hormone refractory prostate cancer J. Urol., 129: 1001–1006, 1983.
4.
RaghavanD.: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Sem. Oncol., 15: 371, 1988.
